Can We Fight Coronavirus Without a Vaccine? Explaining Monoclonal Antibody Research

The Vaccine Integrity Project, in collaboration with the American Medical Association, conducted a vaccine and immunization effectiveness and safety review for RSV, Influenza, and COVID-19 for the 2026-2027 season. JAMA published the review, and here is an overview of the data going into this year's seasonal respiratory virus season.

The 18-year old resident of the state suffered from acute disseminated encephalomyelitis. Pennsylvania numbers are surging with some of the highest state totals of measles cases in the country.

The death was reported in Jefferson County where the coroner released a statement announcing it was in an unvaccinated woman.

FDA approved updated 2026-2027 COVID-19 vaccines from Pfizer-BioNTech, Moderna, and Novavax's partners, all reformulated to target the XFG variant, giving clinicians several options ahead of the fall respiratory virus season.

GSK will advance its investigational mRNA seasonal flu vaccine candidate, which targets both hemagglutinin and neuraminidase, into a phase 3 trial in September 2026 after the shot outperformed licensed flu vaccines in a phase 2 study.

The FDA has approved formulations for the 2026-2027 vaccines including Pfizer-BioNTech's Comirnaty XFG, Novavax's commercial partners Sanofi and Takeda have secured approvals for its Nuvaxovid, and Moderna's Spikevax and mNEXSPIKE vaccines, all with protections against the currently circulating variant.

The FDA has approved Pfizer-BioNTech's 2026-2027 Comirnaty XFG formula, an updated COVID-19 vaccine targeting the XFG variant, for adults 65 and older and for individuals ages five through 64 with at least one high-risk underlying condition.

Gavin Harris, MD, provides some context around what is happening in the Democratic Republic of Congo regarding the outbreak including the country’s inherent challenges as well as discussing the latest in testing, vaccines, and treatments of this rare strain of Ebola.